GPP
ALXN

Great Point Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Great Point Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-110,506
Closed -$13.7M – 45
2018
Q2 		$13.7M Buy
+110,506
New +$12.9M 1.9% 19

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Great Point Partners's ALXN Position: Q3 2018 in Review

Great Point Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 110,506 shares — an estimated $13.7M sold.

Great Point Partners first reported a position in ALXN in Q2 2018 and held it in 1 quarter. The position peaked at $13.7M in Q2 2018. 585 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • Great Point Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Great Point Partners sold 110,506 Alexion Pharmaceuticals shares in Q3 2018, an estimated $13.7M.
  • Great Point Partners first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Great Point Partners's Alexion Pharmaceuticals position peaked at $13.7M in Q2 2018.
  • 585 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Great Point Partners's 13F filing for Q3 2018, filed 14 Nov 2018.